WO1996007655A1 - Nouveau derive de carbapenem - Google Patents

Nouveau derive de carbapenem Download PDF

Info

Publication number
WO1996007655A1
WO1996007655A1 PCT/JP1995/001756 JP9501756W WO9607655A1 WO 1996007655 A1 WO1996007655 A1 WO 1996007655A1 JP 9501756 W JP9501756 W JP 9501756W WO 9607655 A1 WO9607655 A1 WO 9607655A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen atom
lower alkyl
compound
alkyl group
Prior art date
Application number
PCT/JP1995/001756
Other languages
English (en)
Japanese (ja)
Inventor
Susumu Nakagawa
Hiroshi Fukatsu
Yoshiaki Kato
Yuichi Sato
Tomoyasu Kanesaka
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Priority to AU45960/96A priority Critical patent/AU4596096A/en
Publication of WO1996007655A1 publication Critical patent/WO1996007655A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé représenté par la formule générale (I), un procédé de production de ce composé, et l'utilisation de ce composé comme agent antibactérien. Dans cette formule générale (I), R1 représente un hydrogène ou alkyle inférieur, R2 représente un hydrogène, un radical ester ou un métal alcalin, et R3 est un groupe représenté par l'une quelconque des formules générales (a), (b) ou (c) dans lesquelles R4 est un hydrogène, formyle, un alkyle inférieur éventuellement substitué, un alcanoyle inférieur éventuellement substitué ou alkylsulfonyle inférieur éventuellement substitué, R?5, R6 et R7¿ représentent chacun un oxo ou thioxo. Ce composé constitue avantageusement un agent antibactérien car il fait preuve d'une puissante activité antibactérienne contre les bactéries gram-positives et gram-négatives à MRSA et présente une très bonne résistance contre les β-lactamases et le DHD-1, ainsi qu'une bonne innocuité vis-à-vis du système nerveux central. Ses dérivés esters, qui sont administrables par voie perorale, devraient grandement contribuer au traitement des maladies infectieuses.
PCT/JP1995/001756 1994-09-06 1995-09-04 Nouveau derive de carbapenem WO1996007655A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45960/96A AU4596096A (en) 1994-09-06 1995-09-04 Novel carbapenem derivative

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP6/238484 1994-09-06
JP23848494 1994-09-06
JP7228095 1995-03-06
JP7/72280 1995-03-06
USPCT/JP95/01111 1995-06-06
JP9501111 1995-06-06

Publications (1)

Publication Number Publication Date
WO1996007655A1 true WO1996007655A1 (fr) 1996-03-14

Family

ID=27300918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001756 WO1996007655A1 (fr) 1994-09-06 1995-09-04 Nouveau derive de carbapenem

Country Status (2)

Country Link
AU (1) AU4596096A (fr)
WO (1) WO1996007655A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826687A1 (fr) * 1996-08-16 1998-03-04 Suntory Limited Dérivés de carbapenem et agents antimicrobiens les contenant
WO2004035539A1 (fr) * 2002-10-18 2004-04-29 Meiji Seika Kaisha, Ltd. Procede destine a la fabrication de carbapenem et intermediaire utilise dans sa fabrication
US7662872B2 (en) 2005-10-11 2010-02-16 The Yokohama Rubber Co., Ltd. Salt of carboxylic acid containing N-substituted succinimide thio group and unvulcanized rubber composition containing the same
EP3737675A4 (fr) * 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Ligands crbn et leurs utilisations
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60132985A (ja) * 1983-11-21 1985-07-16 メルク　エンド　カムパニー　インコーポレーテツド 環式アミジニル及び環式グアニジニルチオカルバペネム
JPH0249783A (ja) * 1988-05-10 1990-02-20 Sankyo Co Ltd １―メチルカルバペネム誘導体
JPH04279588A (ja) * 1990-09-07 1992-10-05 Tanabe Seiyaku Co Ltd １−メチルカルバペネム誘導体及びその製法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60132985A (ja) * 1983-11-21 1985-07-16 メルク　エンド　カムパニー　インコーポレーテツド 環式アミジニル及び環式グアニジニルチオカルバペネム
JPH0249783A (ja) * 1988-05-10 1990-02-20 Sankyo Co Ltd １―メチルカルバペネム誘導体
JPH04279588A (ja) * 1990-09-07 1992-10-05 Tanabe Seiyaku Co Ltd １−メチルカルバペネム誘導体及びその製法

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826687A1 (fr) * 1996-08-16 1998-03-04 Suntory Limited Dérivés de carbapenem et agents antimicrobiens les contenant
WO2004035539A1 (fr) * 2002-10-18 2004-04-29 Meiji Seika Kaisha, Ltd. Procede destine a la fabrication de carbapenem et intermediaire utilise dans sa fabrication
US7662872B2 (en) 2005-10-11 2010-02-16 The Yokohama Rubber Co., Ltd. Salt of carboxylic acid containing N-substituted succinimide thio group and unvulcanized rubber composition containing the same
EP3737675A4 (fr) * 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Ligands crbn et leurs utilisations
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders

Also Published As

Publication number Publication date
AU4596096A (en) 1996-03-27

Similar Documents

Publication Publication Date Title
KR910010049B1 (ko) 카르바페넴 유도체의 제조방법
CA2118961A1 (fr) Carbapemenes a substituants 2-thio
CA2028176A1 (fr) Composes de carbapenem
WO1996007655A1 (fr) Nouveau derive de carbapenem
KR880001069B1 (ko) 카르바페넴 유도체및 그의 제조방법
WO1997023483A1 (fr) Derives de 1-methylcarbapenem
KR20000052784A (ko) 트리사이클릭 아민 유도체
EP0449191B1 (fr) Dérivés de carbapénème substitués sur la position 2 avec des goupes pyrrolidinylthio substitués
WO1998002431A1 (fr) DERIVES D'AMINOCYCLOPROPANE cis-SUBSTITUES
EP1340756B1 (fr) Nouveaux composes de beta-lactame et leur procede de production
PT87679B (pt) Processo para a preparacao de derivados 2-metoximetil-penemicos e de composicoes farmaceuticas que os contem
HU192819B (en) Process for preparing antibacterial penemic derivatives
WO1997041123A1 (fr) Derives de 1-methylcarbapeneme
AU651505B2 (en) Aminoalkylpyrrolidinylthiocarbapenem derivatives
JP3233434B2 (ja) カルバペネム誘導体
JP2579472B2 (ja) ペネム化合物
EP0411664B1 (fr) Dérivés de 2-(2-vinylpyrrolidinylthio)carbapénème
KR910009270B1 (ko) 카바펜엠 항생제의 제조방법
JPH06500788A (ja) セファロスポリン誘導体およびそれらの同族体
JPH0784473B2 (ja) ペネム誘導体
JP2832742B2 (ja) カルバペネム誘導体
WO1995014692A1 (fr) Derives de carbapenem et leurs procedes de preparation
JPS6261980A (ja) カルバペネム抗生物質
JPH06192273A (ja) カルバペネム−３−カルボン酸エステル誘導体
JP2003183282A (ja) カルバペネム化合物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA